Scrip
Lurasidone filed for schizophrenia in the US
05 January 2010
Ian Haydock
Please Login to read the full article.
05 January 2010
Ian Haydock
Dainippon Sumitomo Pharma (DSP) has filed for the US approval of its atypical antipsychotic agent lurasidone, for the treatment of schizophrenia.
The December 30th NDA included data from over 40 clinical studies involving more than 2,500 patients treated with the molecule, which acts on...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Dainippon Sumitomo's antipsychotic lurasidone positive in second Phase III study
- DSP sees bipolar depression as another major opportunity for lurasidone
- Mixed Phase III results for Dainippon Sumitomo's antipsychotic lurasidone
- Dainippon Sumitomo to pay $2.6 billion for Sepracor
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
